A recent WHO report released in Geneva projected that over 330 million people will be affected by Diabetes by the year 2030. Currently, an estimated 17 million people suffer from diabetes in the US Alone. It is estimated that between 40% - 60% of these patients suffer from Diabetic Autonomic Neuropathy – the most serious and silent consequence of diabetes. In such cases, cardiac consequences are the cause for a 50% mortality rate over the following five years.

Currently, there is no testing done to detect Autonomic Neuropathy, especially outside the US. The American Diabetes Association has recommended HRV testing on annual basis as early as 1988, However, because the tests were time-consuming, not easily done and inaccurate, testing is not widespread. The ANSiscope is a quick and painless way of diagnosing Diabetic Autonomic Neuropathy early and can become a standard test in such cases. The machine gives a reading of neuropathy and the patient can be monitored over time to determine if the neuropathy is stabilizing or advancing.

The ANSiscope display featured shows a 5-minute measurement. The healthy person has a balance that tends towards the parasympathetic pole, reflecting the fact the healthy people have a parasympathetic predominance. The patient with DAN shows a huge sympathetic predominance (as with any misbalanced ANS Condition) and a balance that flares out a lot.

Furthermore, by comparing the indices between the two cases, it shows very clearly that there is high sympathetic activity in the DAN patients. The healthy person has both components working nicely in tandem, whereas in the case of the DAN patient, we can measure an early absence of coupling. For diabetic patients with DAN, the ANSiscope

-Can give very early detection of the autonomic dysfunction and diagnosis of DAN

-Can allow patients to start treatments like blood glucose control a lot earlier

-Can, with its exact and real-time measurement also be used by drug companies to develop Drug to combal DAN.